tag:blogger.com,1999:blog-4900303239154048192.post4917518634402170305..comments2024-03-06T06:34:42.881-05:00Comments on EconoSpeak: Remdesivir and Transfer Pricing Part IIUnknownnoreply@blogger.comBlogger4125tag:blogger.com,1999:blog-4900303239154048192.post-17063563049443721222020-04-01T00:47:03.732-04:002020-04-01T00:47:03.732-04:00judi online terpercaya
here is two fold: (a) they...<a href="http://ceritasatumalam.online/" rel="nofollow"> judi online terpercaya </a><br><br />here is two fold: (a) they will ramp up production like crazy; and (b) they avoid their initial insanely high prices we saw when Hep C treatment was first introduced. But these are not the Master Blogershttps://www.blogger.com/profile/11615104952684939876noreply@blogger.comtag:blogger.com,1999:blog-4900303239154048192.post-7358563644810746462020-03-31T18:22:39.985-04:002020-03-31T18:22:39.985-04:00"If Gilead can not maintain supply d increase..."If Gilead can not maintain supply d increased demand, the FDA authority to authorize another company to make a drug regardless of patent."<br /><br />Gilead often relies on third party contract manufacturers to supply them with treatments they mark up like crazy before selling to patients. In my part II post today I briefly mention this. My hope here is two fold: (a) they will ramp up production like crazy; and (b) they avoid their initial insanely high prices we saw when Hep C treatment was first introduced. But these are not the same issue. pglnoreply@blogger.comtag:blogger.com,1999:blog-4900303239154048192.post-12096552113957639742020-03-31T16:57:10.275-04:002020-03-31T16:57:10.275-04:00Bill - interesting comment. I'll have to go ba...Bill - interesting comment. I'll have to go back and re-read your Angrybear post. On this Gilead "loophole":<br /><br />"Most of their profits for HEP C, etc. would come from outside the US."<br /><br />When their Hep C treatment came out selling for $1000 a day (84 day treatment) the vast majority of their sales were to US patients. Anonymoushttps://www.blogger.com/profile/06551775998021197253noreply@blogger.comtag:blogger.com,1999:blog-4900303239154048192.post-89936079663824022352020-03-31T15:25:25.511-04:002020-03-31T15:25:25.511-04:00Why Would Remdesivir be Designated and Approved as...<b>Why Would Remdesivir be Designated and Approved as Such if not Rare?</b><br /><br />Typically when a disease is labeled as rare, it implies a condition affecting fewer than 200,000 individuals in the United States. To date, the COVID-19 pandemic will affect multiple times the 200,000 before it is under control. The Orphan Drug Act does have an exception for more common diseases with unmet needs which allows the FDA to consider granting orphan drug status to a treatment for;<br /><br />– “a disease affecting over 200,000 persons in the US and<br /><br />– for which there is no reasonable expectation the cost of developing and making available a drug for such disease will be recovered from sales in the US.”<br /><br />It is this provision that Gilead used with its Remdesivir orphan drug application. Most of their profits for HEP C, etc. would come from outside the US. That may have changed now with the COVID 19 pandemic because of Trump and Republicans failing to take action on COVID 19 in January. Time was really of the essence. The narcissitic dumb ass f**k it und we will pay for it. <br /><br />This is part of what I wrote at Angry Bear on March 26 "Patent Protection vs Orphan Drug Market Exclusivity" https://angrybearblog.com/2020/03/patent-protection-vs-market-exclusivity.html<br /><br />Another couple of points:<br /><br />- If Gilead can not maintain supply d increased demand, the FDA authority to authorize another company to make a drug regardless of patent. <br />- Most companies recoup risk adjusted costs or costs through risk adjusted sales in 5 years. There is a 170 page WHO paper on this for Cancer drugs.run75441https://www.blogger.com/profile/03790826995006015721noreply@blogger.com